In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?

When a patient is having a very durable and long-term response to HER2-directed antibody therapy, I would typically stop the therapy only if issues related to it (such as decreased EF) arise or if the patient desires to stop.

To my knowledge, there are no great retrospective reviews or studies guid...

I think this is an important question, and one that I have faced in clinic several times. I agree with everyone that outside of a clinical trial, I would not stop treatment unless the patient feels strongly about it or there are tolerability issues. However, the long tail of the CLEOPATRA trial, whe...